SCHEMBL1283575

SCHEMBL1283575

O=Cc1ccc(OCCc2ccc(Cl)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
MAPT P10636 2/20 0.57
LMNA P02545 1/20 0.57
HPGD P15428 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HSD17B10 Q99714 1/20 0.53
GPR84 Q9NQS5 3/20 0.48
PPARD Q03181 2/20 0.47
PPARA Q07869 2/20 0.47
PPARG P37231 1/20 0.47
MAOB P27338 3/20 0.47
MAOA P21397 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
RAB9A P51151 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LTA4H P09960 1/20 0.44
FFAR1 O14842 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21331832 0.92 ALDH1A1 (0.59) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL2232877 0.85 ALDH1A1 (0.58) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL4048717 0.85 ALDH1A1 (0.58) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL2231514 0.83 ALDH1A1 (0.63) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL7996783 0.83 MAPT (0.57) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL2231178 0.83 ALDH1A1 (0.66) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL2231854 0.83 ALDH1A1 (0.61) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL2232493 0.83 ALDH1A1 (0.63) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL2232274 0.83 ALDH1A1 (0.61) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL12578126 0.83 ALDH1A1 (0.57) ALDH1A1MAPTLMNAHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108409837-B Glycopeptide compound with anti-drug resistance bacterial activity, preparation method and application thereof 上海来益生物药物研究开发中心有限责任公司 2021-09-24 CN claimed
US-20210093691-A1 Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2021-04-01 US claimed
EP-3763728-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) 2021-01-13 EP claimed
WO-2019170046-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海来益生物药物研究开发中心有限责任公司 2019-09-12 WO claimed
US-11696937-B2 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2023-07-11 US disclosed
US-20210093691-A1 Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2021-04-01 US disclosed
EP-3763728-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) 2021-01-13 EP disclosed
WO-2019170046-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海来益生物药物研究开发中心有限责任公司 2019-09-12 WO disclosed
US-20120088778-A1 AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA, INC. (US) 2012-04-12 US disclosed
US-20100256119-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2010-10-07 US disclosed
US-7737285-B2 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. (US) 2010-06-15 US disclosed
US-7714013-B2 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. (US) 2010-05-11 US disclosed
US-20070213347-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents TRANSTECH PHARMA (US) 2007-09-13 US disclosed
US-20070021386-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents TRANSTECH PHARMA (US) 2007-01-25 US disclosed
US-20050032787-A1 Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity SIGMA-TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) 2005-02-10 US disclosed
EP-1482931-A2 MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE Transtech Pharma, Inc. (US) 2004-12-08 EP disclosed
EP-1465858-A2 PHENY(ALKYL)CARBOXYLIC ACID DERIVATIVES AND DIONIC PHENYLALKYLHETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDICINES WITH SERUM GLUCOSE AND/OR SERUM LIPID LOWERING ACTIVITY Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 2004-10-13 EP disclosed
US-20040082542-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-04-29 US disclosed
WO-2003075921-A2 MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE TRANSTECH PHARMA, INC. (US) 2003-09-18 WO disclosed
WO-2003059864-A2 PHENY(ALKYL)CARBOXYLIC ACID DERIVATIVES AND DIONIC PHENYLALKYLHETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDICINES WITH SERUM GLUCOSE AND/OR SERUM LIPID LOWERING ACTIVITY SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256119-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents AGER, S100A4, S100B ALDH1A1 3404/4885MAPT 526/4885LMNA 989/4885
US-20210093691-A1 Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof VIP, CUTA, MGAM ALDH1A1 4289/4885MAPT 3389/4885LMNA 1261/4885
US-20040082542-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents AGER, S100A4, S100B ALDH1A1 3202/4885MAPT 406/4885LMNA 990/4885
US-20070021386-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents AGER, S100A4, S100B ALDH1A1 3093/4885MAPT 430/4885LMNA 943/4885
US-11696937-B2 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof VIP, CUTA, MGAM ALDH1A1 4289/4885MAPT 3389/4885LMNA 1261/4885
US-20120088778-A1 AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS AGER, S100A4, S100B ALDH1A1 3093/4885MAPT 430/4885LMNA 943/4885
US-20070213347-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents AGER, S100A4, S100B ALDH1A1 3093/4885MAPT 430/4885LMNA 943/4885
US-20050032787-A1 Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity LIPC, CPT1A, GPR119 ALDH1A1 1194/4885MAPT 3652/4885LMNA 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.